Revenue
2021
2022
2023
2024
2025
InMed Pharmaceuticals Inc. (INM)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $4.9M | $4.6M | $1.4M | $1.4M | $1.9M | — |
| Gross profit | $1.7M | $1.1M | $1.4M | $543,546 | — | — |
| Research & development | $2.9M | $3.2M | $3.7M | $0.2 | $5.3M | $5.8M |
| Operating expenses | $9.7M | $9.3M | $9.8M | $17.8M | $9.9M | $9.2M |
| Operating income | — | — | −$7.9M | −$18.6M | −$10.2M | — |
| EBITDAderived | — | — | −$7.7M | −$18.4M | −$10.1M | — |
| Net income | −$8.2M | −$7.7M | −$7.9M | −$18.6M | −$10.2M | −$8.9M |
| Basic EPSper diluted share | -$8.36 | -$20.14 | -$3.25 | -$33.17 | -$37.96 | -$1.71 |
| Diluted EPSper diluted share | -$8.36 | -$20.14 | -$3.25 | -$33.17 | -$37.96 | -$1.71 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 8, 2026Form 4 | Vivo Opportunity, LLC +3TenPercentOwner | BuyCommon Shares · indirect | 3.0K | $1.52 | $4.5K | 72.5K |
| Jun 8, 2026Form 4 | Vivo Opportunity, LLC +3TenPercentOwner | BuyCommon Shares · indirect | 29.5K | $1.52 | $44.9K | 718.4K |
| Jun 5, 2026Form 4 | Vivo Opportunity, LLC +3TenPercentOwner | BuyCommon Shares · indirect | 5.0K | $1.57 | $7.9K | 69.6K |
| Jun 5, 2026Form 4 | Vivo Opportunity, LLC +3TenPercentOwner | BuyCommon Shares · indirect | 50.0K | $1.57 | $78.4K | 688.9K |
| Jun 4, 2026Form 4 | Vivo Opportunity, LLC +3TenPercentOwner | BuyCommon Shares · indirect | 618 | $1.57 | $970.26 | 64.5K |